期刊文献+

四项指标联合检测对胸腔积液性质的判断价值 被引量:3

The diagnostic value of multi-indicators detection of pleural effusion for differentiating malignant and benign pleural effusion
下载PDF
导出
摘要 目的探讨癌胚抗原(CEA)、C反应蛋白(CRP)、乳酸脱氢酶(LDH)、腺苷脱氨酶(ADA)检测对胸腔积液性质的诊断价值。方法检测已经病原学或组织病理学明确诊断的胸腔积液患者180例,其中良性胸腔积液90例,恶性胸腔积液90例,检测胸腔积液中CEA、CRP、LDH、ADA含量,应用受试者工作特征曲线评价上述指标对胸腔积液性质判断的价值。结果在良性胸腔积液中,CRP、ADA水平较恶性胸腔积液患者的高,CEA、LDH较恶性胸腔积液的低(P<0.01)。良性胸腔积液组ADA和CRP的阳性率较恶性胸腔积液组高,LDH、CEA阳性率较恶性胸腔积液低(P<0.01)。根据受试者工作特征曲线,联合检测上述四项指标,可显著提高检测的敏感性和阴性预测值。结论 CEA、CRP、LDH、ADA联合检测可提高良、恶性胸腔积液的鉴别诊断价值。 Objective To investigate the diagnostic value of carcinoembryonic antigen (CEA), C reactive protein (CRP), lactate dehydrogenase(LDH), adenosine deaminase (ADA) of pleural effusion for differentiating malignant and benign pleural effusion. Methods CEA, CRP, LDH, ADA in pleural effusion were detected in 90 patients with benign pleural effusion and 90 patients with malignant pleural effusion. ROC curve was used to evaluate the diagnostic sensitivity and negative predictive value of indicators above in differentiating benign and malignant pleural effusion: Results In be- nign pleural effusion, the level of CRP and ADA were higher than those in the patients with malignant pleural effusion, CEA, LDH were lower than those in the patirnts with malignant pleural effusion, the differences had significant differ- ence (P 〈 0.01). The positive rates of CRP and ADA in benign pleural effusion group were higher than those of malig- nant pleural effusion group, the positive rates of CEA and LDH were lower compared with malignant pleural effusion, the differences had significant difference (P 〈 0.01). When the four indicators were combined detected, the sensitivity and negative predictive value improved significantly according to ROC curve. Conclusion The combined detection of CEA, CRP, LDH, ADA can greatly improve the diagnostic value of benign and malignant pleural effusion.
作者 孙波
出处 《中国医药导报》 CAS 2013年第16期163-164,共2页 China Medical Herald
关键词 癌胚抗原 C反应蛋白 乳酸脱氢酶 腺苷脱氨酶 胸腔积液 Carcinoembryonic antigen C reactive protein Lactate dehydrogenase Adenosine deaminase Pleural ef-fusion
  • 相关文献

参考文献8

二级参考文献24

  • 1王爱玲,李清泉.腺苷脱氨酶、干扰素-γ和白细胞介素-6对结核性胸膜炎的诊断价值[J].武汉大学学报(医学版),2005,26(1):117-120. 被引量:10
  • 2林祥伟,黄宇泽,王奕中.结核性与恶性胸腔积液中ADA、CEA及CA-199应用价值探讨[J].放射免疫学杂志,2006,19(4):351-352. 被引量:8
  • 3王露霞,石凌波,成德,刘海英,谢闻悦,黄晓燕,赖续文.用ROC曲线评价血清甘露聚糖抗原检测法对深部念珠菌感染的诊断价值[J].第三军医大学学报,2007,29(7):646-647. 被引量:5
  • 4Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA1523, CA1929, CYFRA2121 and TSA assay in pleural effusions [ J]. Lung Cancer, 2001, 31 ( 1 ) :9-16.
  • 5Valdes L, Pose A, San JE, et al. Tuberculous pleural effusions[J]. Eur J Intern Med, 2003, 14(2) :77-88.
  • 6Kiropoulos TS,Kostikas K,Oikonomidi S,et al.Acute phase markers for the differentiation of infectious and malignant pleural effusions[J].Respir Med,2007,101(5):910.
  • 7Chierakul N,Kanitsap A,Chaiprasert A,et al.A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion[J].Respirology,2004,9(4):568.
  • 8Reechaipichitkul W,Kawamatawong T,Teerajetgul Y,et al.Diagnostic role of pleural fluid adenosine deaminase in tuberculous pleural effusion[J].Southeast Asian Journal of Tropical Medicine and Public Health,2001,32(2):383.
  • 9Ocama I, Martinez-Vazquez JM, Segura RM, et al. Adenosine deaminase in peural fluids. Test for tuberculous pleural effusions [ J ]. Chest, 1983,84 (1):51.
  • 10Castano Vidnaled JL, Amores-Antequers C. Use of pleural fluid C-reactive protein laboratory diagnosis of pleural effusions [J]. Eur J Med, 1992, 1 (4) :201.

共引文献26

同被引文献34

  • 1马雪曼,张培彤.恶性胸腔积液中肿瘤细胞及其相关因子的检测及应用[J].实用癌症杂志,2014,29(3):361-363. 被引量:3
  • 2Van Meter M E M,Mc Kee K Y,Kohlwes R J.Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions:a systematic review[J].Journal of general internal medicine,2011,26(1):70-76.
  • 3Penz E,Mishra E,Davies H,et al.S79 Comparing the quality of life and cost-effectiveness of in dwelling pleural catheter vs.talc pleurodesis for malignant pleural effusions[J].Thorax,2013,68(Suppl 3):A42-A43.
  • 4Marazioti A,Black well T S,Stath opoulos G T.The lymphatic system in malignant pleural effusion.Drain or immune switch?[J].American journal of respiratory and critical care medicine,2014,189(6):626-627.
  • 5Yeo C D,Kim JW,Kim K H,et al.Detection and comparison of EGFR mutations in matched tumor tissues,cell blocks,pleural effusions,and sera from patients with NSCLC with malignant pleural effusion,by PNA clamping and direct sequencing[J].Lung Cancer,2013,81(2):207-212.
  • 6Stathopoulos G T,K alomenidis I.Malignantpleural effusion:tumor–host interactions unleashed[J].American journal of respiratory and critical care medicine,2012,186(6):487-492.
  • 7Demmy TL,GuL,Burkhalter JE,et al.Optimal management of malignant pleural effusions(results of CALGB 30102)[J].Journal of the National Comprehensive Cancer Network,2012,10(8):975-982.
  • 8Boshuizen R C,Sinaasappel M,Vincent A D,et al.Pleural pressure swing and lung expansion after malignant pleural effusion drainage:the benef its of high-temporal resolution pleural manometry[J].Journal of bronchology&interventional pulmonology,2013,20(3):200-205.
  • 9Kastelik JA.Management of malignant pleural effusion [J].Lung,2013,191(2):165-175.
  • 10Nam HS.Malignant pleural effusion:medical approaches for diagnosis and management[J].Tuberc Respir Dis(Seoul),2014,76(5):211-217.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部